Comparison of visual evoked potentials, automated perimetry and frequency-doubling perimetry in early detection of glaucomatous visual field loss.

The present study compares frequency-doubling perimetry (FDP), automated perimetry (AP) and visual evoked potentials (VEP) for their ability to diagnose early glaucoma. In present study 224 patients of Clinic for Eye Diseases, Clinical Hospital "Sestre Milosrdnice" that had diagnosis of open angle glaucoma and glaucomatous visual field loss proven by automated static perimetry on only one eye were performing all three tests. Visual evoked potentials, automated perimetry and frequency-doubling perimetry were performed four times in each patient with six months period in between testing. Significant difference was proven between frequency-doubling perimetry and automated perimetry in favor for FDP in early detection of glaucomatous field loss. There was no significant difference between FDP and VEP neither between VEP and AP measurements. The results of this study indicate that frequency-doubling perimetry is significantly better method for early detection of glaucomatous visual field loss than automated static perimetry.
AuthorsDean Sarić, Zdravko Mandić, Renata Iveković, Mia Zorić Geber, Goran Benić, Zeljka Tomić, Drazen Grgić
JournalCollegium antropologicum (Coll Antropol) Vol. 29 Suppl 1 Pg. 111-3 ( 2005) ISSN: 0350-6134 [Print] Croatia
PMID16193690 (Publication Type: Comparative Study, Evaluation Studies, Journal Article)
  • Automation
  • Early Diagnosis
  • Evoked Potentials, Visual
  • Glaucoma (diagnosis)
  • Glaucoma, Open-Angle (diagnosis)
  • Humans
  • Sensitivity and Specificity
  • Statistics, Nonparametric
  • Visual Field Tests (methods)
  • Visual Fields

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: